Cancer, immunodeficiency and antiretroviral treatment: results from the Australian HIV Observational Database (AHOD)
Article first published online: 30 AUG 2012
© 2012 British HIV Association
Volume 14, Issue 2, pages 77–84, February 2013
How to Cite
Petoumenos, K., van Leuwen, M., Vajdic, C., Woolley, I., Chuah, J., Templeton, D., Grulich, A., Law, M. and the Australian HIV Observational Database (2013), Cancer, immunodeficiency and antiretroviral treatment: results from the Australian HIV Observational Database (AHOD). HIV Medicine, 14: 77–84. doi: 10.1111/j.1468-1293.2012.01038.x
- Issue published online: 2 JAN 2013
- Article first published online: 30 AUG 2012
- Manuscript Accepted: 19 JUN 2012
- U.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID). Grant Number: U01-AI069907
- antiretroviral treatment;
The objective of the study was to conduct a within-cohort assessment of risk factors for incident AIDS-defining cancers (ADCs) and non-ADCs (NADCs) within the Australian HIV Observational Database (AHOD).
A total of 2181 AHOD registrants were linked to the National AIDS Registry/National HIV Database (NAR/NHD) and the Australian Cancer Registry to identify those with a notified cancer diagnosis. Included in the current analyses were cancers diagnosed after HIV infection. Risk factors for cancers were also assessed using logistic regression methods.
One hundred and thirty-nine cancer cases were diagnosed after HIV infection among 129 patients. More than half the diagnoses (n = 68; 60%) were ADCs, of which 69% were Kaposi's sarcoma and 31% non-Hodgkin's lymphoma. Among the NADCs, the most common cancers were melanoma (n = 10), lung cancer (n = 6), Hodgkin's lymphoma (n = 5) and anal cancer (n = 5). Over a total of 21021 person-years (PY) of follow-up since HIV diagnosis, the overall crude cancer incidence rate for any cancer was 5.09/1000 PY. The overall rate of cancers decreased from 15.9/1000 PY [95% confidence interval (CI) 9.25–25.40/1000 PY] for CD4 counts < 100 cells/μL to 2.4/1000 PY (95% CI 1.62–3.39/1000 PY) for CD4 counts > 350 cells/μL. Lower CD4 cell count and prior AIDS diagnoses were significant predictors for both ADCs and NADCs.
ADCs remain the predominant cancers in this population, although NADC rates have increased in the more recent time period. Immune deficiency is a risk factor for both ADCs and NADCs.